AG
NBIX icon

AlTi Global’s Neurocrine Biosciences NBIX Stock Holding History

AlTi Global’s Portfolio NBIX Stock Details NBIX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q1 		– Sell
-6,826
Closed -$968K – 462
2025
Q4 		$968K Sell
6,826
-2
-0% -$290 0.02% 235
2025
Q3 		$959K Buy
6,828
+70
+1% +$9.48K 0.02% 250
2025
Q2 		$902K Buy
6,758
+1
+0% +$115 0.02% 244
2025
Q1 		$747K Buy
6,757
+1,671
+33% +$212K 0.02% 242
2024
Q4 		$729K Buy
+5,086
New +$629K 0.02% 247

Other funds holding NBIX

BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
Dodge & Cox
Dodge & Cox San Francisco, California $182B AUM 14.68% 1-Year Est. Return
JP Morgan Chase
JP Morgan Chase New York $1.56T AUM 27.86% 1-Year Est. Return
AQR Capital Management
AQR Capital Management Greenwich, Connecticut $218B AUM 29.41% 1-Year Est. Return
VPM
Vanguard Portfolio Management Malvern, Pennsylvania $1.91T AUM
VCM
Vanguard Capital Management Malvern, Pennsylvania $4.04T AUM
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
Two Sigma Investments
Two Sigma Investments New York $124B AUM 33.93% 1-Year Est. Return
Renaissance Technologies
Renaissance Technologies New York $63.9B AUM 45.56% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return

AlTi Global's NBIX Position: Q1 2026 in Review

AlTi Global sold out of Neurocrine Biosciences (NBIX) in Q1 2026, closing a stake of 6,826 shares — an estimated $968K sold.

AlTi Global first reported a position in NBIX in Q4 2024 and held it in 5 quarters. The position peaked at $968K in Q4 2025. 696 funds tracked by Wall St. Rank hold NBIX as of Q1 2026.

  • AlTi Global reported no remaining Neurocrine Biosciences position as of Q1 2026 after selling out during the quarter.
  • AlTi Global sold 6,826 Neurocrine Biosciences shares in Q1 2026, an estimated $968K.
  • AlTi Global first reported a position in Neurocrine Biosciences in Q4 2024 and held it in 5 quarters.
  • AlTi Global's Neurocrine Biosciences position peaked at $968K in Q4 2025.
  • 696 funds tracked by Wall St. Rank held Neurocrine Biosciences as of Q1 2026.

Based on AlTi Global's 13F filing for Q1 2026, filed 7 May 2026.